Négociation Vor Biopharma Inc. - VOR CFD

Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company''s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.